The company anticipates it will report positive net income for the full year 2025, while funding existing and new clinical development programs.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- RIGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Rigel Pharmaceuticals enrolls first patient in Phase 1 study of fostamatinib
- Rigel Pharmaceuticals sees Q4 revenue $57.6M, consensus $47.42M
- Rigel Pharmaceuticals sees FY25 revenue $200M-$210M, consensus $193.51M
- Rigel announces R289 granted Orphan Drug designation by FDA for MDS